SOURCE-LINKED STUDY SUMMARY
Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.
Full paper summarizedQuality not appraised
- What was studied
- A double-blind randomized trial examined urolithin A effects on immune-cell composition and metabolism.
- Who / model studied
- 50 healthy middle-aged adults.
- Studied dose & schedule
- Oral urolithin A 1,000 mg/day or placebo for 4 weeks.
- What the study found
- Naive-like CD8 cells increased by 0.50 percentage points versus placebo, and CD8 fatty-acid oxidation capacity by 14.72 percentage points. These were laboratory immune outcomes.
- Limitations & context
- Short, manufacturer-funded study, not evidence of fewer infections or longer life. The author correction replaced a duplicated figure panel. Selected full-paper passages and correction checked.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s43587-025-00996-x